Brief Reports
Lipid-Lowering Therapy and Long-Term Survival in Heart Transplantation

https://doi.org/10.1016/S0002-9149(97)00524-9Get rights and content

First page preview

First page preview
Click to open first page preview

References (13)

There are more references available in the full text version of this article.

Cited by (20)

  • Treatment of hyperlipidemia in cardiac transplant recipients

    2004, American Heart Journal
    Citation Excerpt :

    When a fibrate is deemed appropriate in a given patient, 600 mg of gemfibrozil daily should be used preferentially, although 54 mg of fenofibrate daily may be used as an alternative. Gemfibrozil is generic, less expensive than fenofibrate, has less reported nephrotoxicity, and has been associated with improved survival rates in CT recipients in a non-randomized trial.40 Fenofibrate has a slightly higher rate of nephrotoxicity when used with cyclosporine, but may have decreased pharmokinetic effects on statins as compared with gemfibrozil and appears to be better tolerated by some patients.

  • Impact of lipid abnormalities in development and progression of transplant coronary disease: A serial intravascular ultrasound study

    2001, Journal of the American College of Cardiology
    Citation Excerpt :

    Further, in a subgroup of patients, intracoronary ultrasound measurements at baseline and one year after transplantation showed less progression in maximal intimal thickness with pravastatin treatment. Two other investigations have confirmed the survival benefit of cholesterol lowering in transplant recipients (7,8). Our study underscores the importance of change in lipid values on progression of transplant vasculopathy.

  • Management of selected lipid abnormalities: Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation

    2001, Cardiology Clinics
    Citation Excerpt :

    Most heart transplant patients are also hyperlipidemic,16 and there may be an association between hyperlipidemia and development of accelerated cardiac graft vasculopathy,16,28 although Lp(a) levels do not appear to be a risk factor.28 Lipid-lowering drug therapy appeared to confer a survival benefit in cardiac transplant patients who survive beyond the first year.110 Treatment of hyperlipidemia after heart transplant is advisable, and a Heart Transplant Lipid Registry has been formed to track outcomes in heart transplant recipients relative to lipid management.15

View all citing articles on Scopus
View full text